GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adlai Nortye Ltd (NAS:ANL) » Definitions » Short-Term Debt

ANL (Adlai Nortye) Short-Term Debt : $38.89 Mil (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Adlai Nortye Short-Term Debt?

Adlai Nortye's Short-Term Debt for the quarter that ended in Jun. 2024 was $38.89 Mil.

Adlai Nortye's quarterly Short-Term Debt increased from Jun. 2023 ($19.50 Mil) to Dec. 2023 ($30.36 Mil) and increased from Dec. 2023 ($30.36 Mil) to Jun. 2024 ($38.89 Mil).

Adlai Nortye's annual Short-Term Debt declined from Dec. 2021 ($10.46 Mil) to Dec. 2022 ($4.31 Mil) but then increased from Dec. 2022 ($4.31 Mil) to Dec. 2023 ($30.36 Mil).

Adlai Nortye Short-Term Debt Historical Data

The historical data trend for Adlai Nortye's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adlai Nortye Short-Term Debt Chart

Adlai Nortye Annual Data
Trend Dec21 Dec22 Dec23
Short-Term Debt
10.46 4.31 30.36

Adlai Nortye Quarterly Data
Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23 Jun24
Short-Term Debt Get a 7-Day Free Trial 4.31 10.19 19.50 30.36 38.89

Adlai Nortye Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Adlai Nortye Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Adlai Nortye's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Adlai Nortye Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adlai Nortye Ltd (NAS:ANL) » Definitions » Short-Term Debt
Comparable Companies
ABOS IVVD CLSD MNOV AVTE ACRV NTRB EPIX IGMS DOMH VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N2U0:Germany
Address
685 US Highway 1, New Jersey Biotechnology Development Center, 2nd floor, North Brunswick, NJ, USA, 08902
Website
https://www.adlainortye.com
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.